Psoriasis Treatment Market Size to Hit USD 87.6 Billion by 2035 Amid Rising Adoption of Advanced Immunotherapies - TMR Analysis

Psoriasis Treatment Market Size -

The global Psoriasis Treatment Market was valued at US$ 35.0 billion in 2024 and is projected to expand at a CAGR of 9.5% from 2025 to 2035, surpassing US$ 87.6 billion by the end of 2035. Growth in the market is driven by the rising prevalence of psoriasis worldwide, increased awareness of advanced biologic and biosimilar therapies, and the introduction of innovative treatment options that offer improved efficacy and safety profiles.

👉 Don't miss out on the latest market intelligence. Get your sample report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Market Overview -

The Psoriasis Treatment Market includes therapies designed to manage chronic, immune-mediated inflammatory skin disorders that cause red, scaly patches. The disease affects millions globally, with increasing incidence due to genetic predisposition, lifestyle changes, and environmental factors. The market encompasses a wide range of treatments, including topical agents, systemic drugs, biologics, and phototherapy.

The growing adoption of targeted biologics and small molecule inhibitors is reshaping the treatment landscape, offering more precise and long-lasting disease control. Furthermore, increasing research funding, a robust clinical pipeline, and the expansion of teledermatology are enhancing patient access and treatment adherence worldwide.

Market Description -

Psoriasis treatment focuses on reducing inflammation, controlling overactive immune responses, and improving skin regeneration. Treatment approaches are tailored to the severity and type of psoriasis, ranging from mild topical solutions to advanced biologic therapies.

Recent advances in immunomodulators and Janus kinase (JAK) inhibitors have revolutionized care by providing more convenient and effective therapeutic options. Biologic drugs targeting IL-17, IL-23, and TNF-α pathways have shown remarkable clinical outcomes, reducing flare-ups and improving quality of life.

Additionally, the emergence of biosimilars, personalized medicine, and digital treatment monitoring platforms has created new growth opportunities within the market.

Analysis of Key Players in the Psoriasis Treatment Market

The global psoriasis treatment market is characterized by the presence of several major pharmaceutical and biotechnology companies investing in advanced therapeutics, biologics, and novel drug delivery systems. Leading players are focusing on strategic collaborations, R&D initiatives, and regulatory approvals to expand their treatment portfolios and strengthen their foothold in emerging and developed markets.

Prominent companies operating in the market include
• Bristol-Myers Squibb Company
• AbbVie Inc
• Amgen Inc
• AstraZeneca
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• LEO Pharma A/S
• Merck & Co., Inc.,
• Novartis AG
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Arcutis Biotherapeutics, Inc
• Dermavant Sciences, Inc.
• TIEFENBACHER GROUP
• UCB S.A.
• Bausch Health
• Sun Pharmaceutical Industries Limited
• Akeso Biopharma Co., Ltd.
• Other Prominent Players.

Each of these players has been profiled in the Psoriasis Treatment Market Research Report based on parameters such as company overview, financial performance, business strategies, product portfolio, business segments, and recent developments.

📌 Detailed strategy mapping is available in the sample report copy - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Key Developments in the Psoriasis Treatment Market

• August 2024: Amgen Inc. announced that Otezla® (apremilast) is now available in the U.S. for pediatric use. The drug is approved for treating moderate to severe plaque psoriasis in children and adolescents aged 6 years and older who weigh at least 20 kg (44 lb) and are eligible for phototherapy or systemic therapy. Notably, Otezla remains the only FDA-approved oral medication for moderate to severe plaque psoriasis in this age group.

• September 2022: Bristol Myers Squibb received U.S. FDA approval for Sotyktu® (deucravacitinib), a first-in-class, oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor. The drug is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, marking a significant milestone in oral treatment options for psoriasis patients.

Key Player Strategies -

• Biologic Innovation: Development of next-generation biologics and biosimilars targeting specific immune pathways.
• Oral Small Molecule Drugs: Expanding portfolios with JAK and TYK2 inhibitors for improved patient convenience.
• Strategic Collaborations: Partnering with biotech firms and academic institutions to advance R&D in dermatological therapeutics.
• Geographical Expansion: Strengthening presence in emerging markets through strategic alliances and cost-effective treatment solutions.
• Patient-Centric Programs: Offering support initiatives, education campaigns, and digital adherence tools to improve treatment outcomes.

Challenges -

• High Cost of Biologics: Premium pricing of biologic drugs limits access in cost-sensitive markets.
• Side Effects and Resistance: Long-term use may cause reduced efficacy or adverse immune responses.
• Reimbursement Barriers: Inconsistent insurance coverage for newer therapies hinders widespread adoption.
• Limited Access in Developing Regions: Lack of dermatological specialists and infrastructure affects treatment penetration.

Opportunities -

• Emergence of Biosimilars: Affordable biosimilar biologics to increase treatment accessibility globally.
• R&D in Precision Medicine: Genetic profiling and AI-driven diagnostics enabling personalized therapy selection.
• Teledermatology and E-Health: Digital platforms improving patient monitoring and remote disease management.
• Focus on Comorbidities: Growing research linking psoriasis with cardiovascular and metabolic diseases expands treatment scope.
• Awareness Programs: Increased campaigns by healthcare bodies and patient advocacy groups driving early diagnosis.

Market Segmentations -

By Drug Class:
• TNF Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors
• PDE4 Inhibitors
• Corticosteroids
• Vitamin D Analogues
• Retinoids
• Others

By Type:
• Plaque Psoriasis
• Guttate Psoriasis
• Inverse Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis

By Route of Administration:
• Oral
• Topical
• Injectable

By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:
• North America: Dominates due to high disease prevalence, robust healthcare infrastructure, and access to advanced biologics.
• Europe: Significant market share supported by government initiatives and biosimilar adoption.
• Asia-Pacific: Fastest-growing region driven by rising awareness, improving healthcare access, and growing middle-class population.
• Latin America & Middle East & Africa: Emerging markets showing potential due to increasing dermatology awareness programs.

Why Buy This Report?

• Comprehensive Market Overview: Gain insights into the evolving psoriasis treatment landscape and its key growth drivers.
• Segmented Analysis: Understand opportunities across drug classes, treatment types, and regions.
• Competitive Landscape: Review leading players' strategies and product pipelines.
• Accurate Forecasts: Access reliable projections to support investment and strategic planning.
• Emerging Opportunities: Identify areas of growth, including biosimilars, digital health, and personalized therapies.
• Expert Recommendations: Obtain actionable insights for enhancing market presence and profitability.

👉 Purchase the full report now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=17960<ype=S

Conclusion -

The Psoriasis Treatment Market is poised for significant expansion, fueled by breakthroughs in biologic therapies, rising healthcare investments, and increasing patient awareness. The integration of AI in dermatology, biosimilar development, and telehealth-based management is transforming how psoriasis is treated worldwide. While affordability and accessibility remain key challenges, continued innovation and policy support are expected to make psoriasis treatments more inclusive and effective, ensuring a better quality of life for millions of patients globally.

More Trending Research Reports-

• Parenteral Nutrition Market - https://www.transparencymarketresearch.com/parenteral-nutrition-market.html
• Abortion Drugs Market - https://www.transparencymarketresearch.com/abortion-drugs-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.